Literature DB >> 9647333

Gene expression of endothelin-1 and ET(A) and ET(B) receptors in human cirrhosis: relationship with hepatic hemodynamics.

A Leivas1, W Jiménez, J Bruix, L Boix, J Bosch, V Arroyo, F Rivera, J Rodés.   

Abstract

Previous experimental studies have suggested that the paracrine endothelin system may participate in the regulation of hepatic hemodynamics in cirrhosis. The present study assesses the relationship between increased portal pressure and preproET-1, ET(A) receptor and ET(B) receptor gene expression in human cirrhosis. PreproET-1, ET(A) receptor and ET(B) receptor mRNA abundance was estimated by quantitative PCR in human hepatic tissue from subjects with normal liver and in cirrhotic patients in whom a hepatic hemodynamic study was performed. The expression of the three transcripts was significantly higher in liver samples of cirrhotic patients than in those obtained from subjects without any histological alteration. Moreover, while no significant correlation was found between preproET-1 mRNA abundance and portal pressure, there was a highly significant direct relationship between ET(A) and ET(B) receptor gene expression and portal pressure in cirrhotic patients. These results indicate that the liver paracrine endothelin system is overactivated in human cirrhosis and that a direct relationship exists between endothelin receptor mRNA abundance and the degree of portal hypertension in these patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9647333     DOI: 10.1159/000025583

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  18 in total

Review 1.  Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension.

Authors:  H Reynaert; M G Thompson; T Thomas; A Geerts
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

2.  Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial.

Authors:  D Tripathi; G Therapondos; J W Ferguson; D E Newby; D J Webb; P C Hayes
Journal:  Gut       Date:  2006-01-24       Impact factor: 23.059

3.  Endotoxin causes up-regulation of endothelin receptors in cultured hepatic stellate cells via nitric oxide-dependent and -independent mechanisms.

Authors:  C R Gandhi; T Uemura; R Kuddus
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

4.  Prevention and treatment of Schistosoma mansoni-induced liver fibrosis in mice.

Authors:  Dina S El-Agamy; Abdelhadi M Shebl; Shehta A Said
Journal:  Inflammopharmacology       Date:  2011-09-23       Impact factor: 4.473

5.  The endothelin/nitric oxide balance determines small-for-size liver injury after reduced-size rat liver transplantation.

Authors:  Daniel Palmes; Evgeny Minin; Tymoteusz Budny; Dirk Uhlmann; Barbara Armann; Udo Stratmann; Hermann Herbst; Hans-Ullrich Spiegel
Journal:  Virchows Arch       Date:  2005-10-19       Impact factor: 4.064

Review 6.  Endothelin-1 in the pathophysiology of obesity and insulin resistance.

Authors:  Haley N Jenkins; Osvaldo Rivera-Gonzalez; Yann Gibert; Joshua S Speed
Journal:  Obes Rev       Date:  2020-07-06       Impact factor: 9.213

7.  11,12-EET increases porto-sinusoidal resistance and may play a role in endothelial dysfunction of portal hypertension.

Authors:  David Sacerdoti; Houli Jiang; Silvia Gaiani; John C McGiff; Angelo Gatta; Massimo Bolognesi
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-08-11       Impact factor: 3.072

Review 8.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

9.  Endothelin receptor antagonist TAK-044 arrests and reverses the development of carbon tetrachloride induced cirrhosis in rats.

Authors:  C Thirunavukkarasu; Y Yang; V M Subbotin; S A K Harvey; J Fung; C R Gandhi
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

10.  Endothelin and vascular function in liver disease.

Authors:  K Moore
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.